이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Co-development of a Deprescribing Program for Older Community-dwelling Patients Treated With Anticholinergic/Sedative Medications (CC-DIOPAS)

2026년 6월 25일 업데이트: Hospices Civils de Lyon

Co-development of a Multidisciplinary, Participatory Deprescribing Program for Older Community-dwelling Patients Treated by Medications With Anticholinergic and/or Sedative Properties

About 20% of emergency room admissions among people over the age of 75 are related to medication-induced adverse events. These events are exacerbated by polypharmacy, which can be inappropriate when prescribed medications have an uncertain benefit-risk balance or cause harmful drug interactions. Among potentially inappropriate medications (PIMs), those with anticholinergic and/or sedative properties are the most harmful to older adults and yet are very frequently prescribed. Indeed, in France, 33% of older patients living at home are treated with this type of medication, the use of which is associated with cognitive decline, falls, functional decline (loss of independence), excess mortality, reduced quality of life, and hospitalizations.

Thus, reducing the burden of anticholinergic and sedative medications in older adults is a key priority in the prevention of iatrogenic risk. Among the strategies developed to reduce the use of PIMs in older patients, deprescribing interventions-defined as the supervised discontinuation of inappropriate treatment-have been gradually implemented in recent years. However, few interventional studies on the deprescribing of anticholinergic and/or sedative medications have demonstrated positive results. To better understand the inconsistent effectiveness of deprescribing programs, studies have been conducted to identify the barriers and facilitators of deprescribing, and three key areas have been identified to facilitate the implementation of such programs:

  • Involve and support patients in the co-design of the intervention (participatory research) and throughout the intervention itself to reach a shared decision.
  • Work in an interdisciplinary manner by combining the areas of expertise of outpatient healthcare professionals regarding patient knowledge and support with the expertise of hospital-based professionals in the field of aging.
  • Work in a coordinated manner to foster interprofessional cooperation and ensure the transferability of the deprescribing pathway in real-world settings through multi-professional consultation.

The DIOPAS project aims to develop and implement a multidisciplinary, participatory deprescribing program for older community-dwelling patients being treated by medications with anticholinergic and/or sedative properties. The first step involves the co-development of the intervention, which is the focus of this CC-DIOPAS study. This study proposes a participatory co-development approach to the intervention, bringing together the various types of professionals (from both primary care and hospital) involved in medication optimization, as well as community-dwelling patients and patient partners.

연구 개요

연구 유형

관찰

등록 (실제)

35

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Villeurbanne, 프랑스, 69100
        • Hôpital des Charpennes, Institut du Vieillissement

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

샘플링 방법

비확률 샘플

연구 인구

  • Hospital healthcare professionals involved in geriatric outpatient care and in the medication management of older patients: geriatricians, hospital pharmacists, and nurses
  • Primary care healthcare professionals involved in the medication management of the target population: general practitioners, community pharmacists, and private practice nurses
  • Patients who met the study's eligibility criteria regarding age and polypharmacy so that the co-designed intervention takes into account their needs and expectations, as well as their opinions regarding the methodology used (participative research). Partner patients will also be solicited.

설명

Inclusion Criteria:

  • Healthcare Professionals:

In hospitals:

  • Geriatricians, hospital pharmacists, or registered nurses;
  • Practicing in a geriatric day hospital at the university hospitals in Lyon, Grenoble, Marseille, Nîmes, or Nantes;
  • Agree to participate in focus group meetings or the working group.

In primary care facilities:

  • General practitioners, community pharmacists, or independent registered nurses;
  • Practicing within a primary care facility in the geographic areas served by the university hospitals of Lyon, Grenoble, Marseille, Nîmes, or Nantes;
  • Agree to participate in focus group meetings or the working group.

Patients:

Patients of the primary care facilities :

  • Patients aged 65 to 80;
  • Patients receiving outpatient care (not hospitalized) at a primary care facility within the geographic areas of the University Hospitals of Lyon;
  • Patients taking at least 5 chronic medications prescribed per day (polypharmacy);
  • Agree to participate in focus group meetings or the working group;

Partner patients:

  • Partner patients of the Lyon University Hospital or the RESHAPE laboratory;
  • Agree to participate in meetings of the working group or the study's scientific advisory board.

Exclusion Criteria:

  • None

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
Healthcare professionals and patients
Health professionals and patients will be asked during focus groups and workshop on the co-developed deprescribing program

This is a qualitative study conducted in two successive phases. First, three focus groups comprising patients and healthcare professionals from both hospital and primary care settings will assess their needs, expectations, and initiatives regarding support for deprescribing, and identify the barriers and facilitators to implement a multidisciplinary pathway.

In a second phase, a multidisciplinary working group will be tasked with developing a logic model for deprescribing. This group will include hospital-based healthcare professionals, primary care professionals, and patients, with the aim of designing an intervention that is both implementable and transferable to real-world settings (2-5 workshops).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Logic model for the deprescribing pathway
기간: Through study completion, an average of 6 months (Following the last working group meeting)
Logic model for the community-to-hospital deprescribing pathway (DIOPAS intervention), developed by the mixed working group.
Through study completion, an average of 6 months (Following the last working group meeting)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 28일

기본 완료 (실제)

2025년 11월 27일

연구 완료 (실제)

2026년 1월 16일

연구 등록 날짜

최초 제출

2026년 6월 2일

QC 기준을 충족하는 최초 제출

2026년 6월 25일

처음 게시됨 (실제)

2026년 6월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 26일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 6월 25일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다